UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study

Hypertension (Dallas, Tex. 1979), 2005-02, Vol.45 (2), p.198-202

2005

Volltextzugriff (PDF)

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

Kidney international, 2004-03, Vol.65 (3), p.1041-1049

2004

Volltextzugriff (PDF)

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

Journal of hypertension, 2004-09, Vol.22 (9), p.1805-1811

2004

Volltextzugriff (PDF)

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

Hypertension (Dallas, Tex. 1979), 2005-01, Vol.45 (1), p.46-52

2005

Volltextzugriff (PDF)

The Losartan Intervention For Endpoint Reduction (LIFE) in hypertension study: Rationale, design, and methods

American journal of hypertension, 1997-07, Vol.10 (7), p.705-713

1997

Volltextzugriff (PDF)

Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy : The LIFE (losartan intervention for endpoint reduction in hypertension) study

Circulation (New York, N.Y.), 2005-04, Vol.111 (15), p.1924-1931

2005

Volltextzugriff (PDF)

Pulse Pressure and Effects of Losartan or Atenolol in Patients With Hypertension and Left Ventricular Hypertrophy

Hypertension (Dallas, Tex. 1979), 2005-04, Vol.45 (4), p.580-585

2005

Volltextzugriff (PDF)

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study

Journal of the American College of Cardiology, 2005-09, Vol.46 (5), p.770

2005

Volltextzugriff (PDF)

Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy

Current medical research and opinion, 2007-02, Vol.23 (2), p.259-270

2007

Volltextzugriff (PDF)

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

The Lancet (British edition), 2002-03, Vol.359 (9311), p.995-1003

2002

Volltextzugriff (PDF)

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

The Lancet (British edition), 2002-03, Vol.359 (9311), p.1004-1010

2002

Volltextzugriff (PDF)

Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

Blood pressure, 2009, Vol.18 (6), p.348-361

2009

Volltextzugriff (PDF)

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

Annals of internal medicine, 2003-12, Vol.139 (11), p.901

2003

Volltextzugriff (PDF)

Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study

American journal of hypertension, 2000-08, Vol.13 (8), p.899-906

2000

Volltextzugriff (PDF)

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

JAMA : the journal of the American Medical Association, 2002-09, Vol.288 (12), p.1491

2002

Volltextzugriff (PDF)

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Journal of hypertension, 2002-09, Vol.20 (9), p.1879-1886

2002

Volltextzugriff (PDF)

Comparison of Acute Effects of Nifedipine in Normotensive and Hypertensive Man

Journal of cardiovascular pharmacology, 1980-07, Vol.2 (4), p.357-366

1980

Volltextzugriff (PDF)

Reducing Microalbuminuria-Does It Lower Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005

Journal of the American Society of Nephrology, 2005-09, Vol.16 (9), p.2521-2527

2005

Volltextzugriff (PDF)

Lowering Albuminuria-Does It Lower the Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005

Journal of the American Society of Nephrology, 2005-08, Vol.16 (8), p.2247-2250

2005

Volltextzugriff (PDF)

Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study

Journal of human hypertension, 2004-06, Vol.18 (6), p.381-389

2004

Volltextzugriff (PDF)

Renal effects of acute calcium blockade with nifedipine in hypertensive patients receiving beta-adrenoceptor-blocking drugs

Clinical pharmacology and therapeutics, 1982-11, Vol.32 (5), p.572-576

1982

Volltextzugriff (PDF)

Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: The LIFE study

Blood pressure, 2004, Vol.13 (6), p.376-384

2004

Volltextzugriff (PDF)

Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study

Hypertension (Dallas, Tex. 1979), 1998-12, Vol.32 (6), p.989-997

1998

Volltextzugriff (PDF)

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

Journal of hypertension, 2009-03, Vol.27 (3), p.567-574

2009

Volltextzugriff (PDF)

Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial

Annals of internal medicine, 2003-08, Vol.139 (3), p.169

2003

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(87)

Publikationsform

Artikel
(98)
Tagungsberichte
(5)

Erscheinungsjahr

n.n

Thema

Humans
(73)
Science & Technology
(71)
Life Sciences & Biomedicine
(70)
Male
(65)
Female
(57)
Middle Aged
(57)
Hypertension - Drug Therapy
(51)
Aged
(34)
Biological And Medical Sciences
(33)
Medical Sciences
(33)
Pharmacology & Pharmacy
(32)
Adult
(31)
Blood Pressure - Drug Effects
(31)
Medicin Och Hälsovetenskap
(29)
Cardiovascular System & Cardiology
(28)
Hypertension - Physiopathology
(28)
Hypertension
(27)
Cardiovascular System
(24)
Antihypertensive Agents - Therapeutic Use
(23)
Pharmacology. Drug Treatments
(23)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

The Losartan Intervention For Endpoint Reduction (LIFE) in hypertension study: Rationale, design, and methods

Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy : The LIFE (losartan intervention for endpoint reduction in hypertension) study

Pulse Pressure and Effects of Losartan or Atenolol in Patients With Hypertension and Left Ventricular Hypertrophy

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study

Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Comparison of Acute Effects of Nifedipine in Normotensive and Hypertensive Man

Reducing Microalbuminuria-Does It Lower Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005

Lowering Albuminuria-Does It Lower the Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005

Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study

Renal effects of acute calcium blockade with nifedipine in hypertensive patients receiving beta-adrenoceptor-blocking drugs

Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: The LIFE study

Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial

Aktive Filter

Suchergebnisse filtern